Advertisement

Topics

UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure

03:01 EDT 9 Aug 2017 | Labiotech.eu

Zynerba Pharmaceuticals cannabinoid drug for epilepsy missed all of its endpoints costing the company’s stock price more than 55% — and GW Pharma 8.6%. On Monday, Zynerba Pharmaceuticals, a Pennsylvania-based biotech, announced that its transdermal cannabinoid candidate ZYN002 for refractory ...

This awesome article UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure

NEXT ARTICLE

More From BioPortfolio on "UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...